Novel *FARS2* mutations in patients with non-fatal early onset encephalopathy with or without epilepsy

Giulia Barcia[1,2], Marlène Rio[1], Zahra Assouline[1,2], Coralie Zangarelli[3], Charles-Joris Roux[4], Pascale de Lonlay[5], Julie Steffann[1,2,3], Isabelle Desguerre[6], Arnold Munnich[1,2,3], Jean-Paul Bonnefont[1,2,3], Nathalie Boddaert[4], Agnès Rötig[2,3], Metodi D. Metodiev[3], Benedetta Ruzzenente[3£]

[1] Department of Genetics, Necker Enfants Malades Hospital, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

[2] French Reference Center for Mitochondrial Diseases (CARAMMEL).

[3] Laboratory for Genetics of Mitochondrial Disorders, UMR U1163, Paris Descartes-Sorbonne Paris Cité University, Imagine Institute, Paris, France.

[4] Department of Pediatric Radiology, INSERM UMR 1163, INSERM U1000, Necker Enfants Malades Hospital, Imagine Institute, Paris Descartes-Sorbonne Paris Cité University, Paris, France.

[5] Reference Center for Inherited Metabolic Diseases, Necker Enfants Malades Hospital, Imagine Institute, Paris Descartes University, INEM-1151, G2M, MetabERN, Paris, France.

[6] Department of Pediatric Neurology, Necker Enfants Malades Hospital, Paris Descartes University, Paris, France.

[£], correspondence: Benedetta Ruzzenente, Imagine Institute, Genetics of Mitochondrial Disorders, 75015 Paris, France; e-mail: benedetta.ruzzenente@inserm.fr

Abstract

Mitochondrial translation is essential for the biogenesis of the mitochondrial oxidative phosphorylation system (OXPHOS) that synthesizes the bulk of ATP for the cell. Mutations in either mitochondrial DNA or in nuclear genes that encode mitochondrial translation factors can result in impaired OXPHOS biogenesis and mitochondrial diseases with variable clinical presentations.

Mutations in the *FARS2* gene encoding the mitochondrial phenylalanyl-tRNA synthetase are commonly linked to either early-onset epileptic mitochondrial encephalopathy or spastic paraplegia. Here, we expand the genetic spectrum of *FARS2*-linked disease with three patients carrying novel compound heterozygous variants in the *FARS2* gene and presenting with spastic tetraparesis, axial hypotonia and myoclonic epilepsy in two cases.

Introduction

Mitochondria contain their own translation system complete with a mitochondria-specific ribosome (mitoribosome) and translation factors that function like their cytosolic counterparts but are encoded by distinct nuclear genes. Intramitochondrial translation of mitochondrial DNA (mtDNA)-encoded proteins is essential for the biogenesis of four of the five multiprotein complexes that form the ATP-producing oxidative phosphorylation system (OXPHOS). Inhibition of mitochondrial translation results in isolated or multiple OXPHOS deficiencies and mitochondrial disease.

FARS2 (OMIM# 611592) encodes the mitochondrial phenylalanyl-tRNA synthetase (mtPheRS), which charges mt-tRNA^{Phe} with phenylalanine for translation. MtPheRS contains four major domains—N-terminal, catalytic domain, a linker region (residues 290–322) and an anticodon-

binding domain (ABD)—whose complex interactions and conformational changes enable it to function as a monomer during aminoacylation *(1,2)*. To date, 31 *FARS2* mutations have been linked to two major clinical presentations: a) early-onset epileptic mitochondrial encephalopathy in about two-thirds of the cases *(3-11)*; and b) spastic paraplegia *(12-14)*. While the former group has a typically poorer prognosis, the latter is associated with less severe disease and prolonged survival. MRI studies of patients with early-onset disease often reveal global brain atrophy, cerebellar and basal ganglia abnormalities. In the second group, spastic paraplegia is associated with weakness of the lower extremities, spasticity and difficulties walking. Intellectual disability/developmental delay may be observed in both groups. Here, we report the identification of 4 novel disease-causing variants in the *FARS2* gene in three unrelated patients (Pts) presenting with spastic tetraparesis, developmental delay and myoclonic epilepsy in two cases.

Subjects and methods

Informed consent was obtained for all patients in accordance with the Declaration of Helsinki protocols and approved by local institutional review boards in Paris.

Detailed clinical presentations of the patients are shown in Table 1. Briefly, all three patients (Pts 1, 2 and 3) were born to non-consanguineous parents (Figure 1A) and presented with disease within the first weeks of life. They all had developmental delay and axial hypotonia. Pts 1 and 2 developed spastic quadriplegia. Pts 2 and 3 developed pharmaco-resistant epileptic seizures, mainly myoclonic and associated with a marked photosensitivity in Pt 2; brain MRI showed variably severe ventriculomegaly (Pts 1, 2 and 3) and brain-stem and basal ganglia involvement (Pts 2 and 3) (Figure 1B).

Pathogenic variants were identified using a next generation sequencing panel targeting 382 genes involved in mitochondrial diseases (Pts1 and 3) or whole exome sequencing (Pt 2). The variants were assessed *in silico*, confirmed by Sanger sequencing and segregation analysis as in *(15)*.

Skin fibroblast cultures from controls and patients, protein extraction and immunoblotting were carried out as in *(16)*. MtPheRS antibody was purchased from Proteintech (Manchester, UK, 16436-1-AP). The remaining antisera used here were described previously *(16)*.

Results

All three patients carried compound heterozygous variants including four missense mutations c.1256G>A p.(Arg419His), c.989G>A p.(Arg330His), c.1113G>T p.(Leu371Phe) and c.251A>C p.(His84Pro) all affecting evolutionary conserved amino acids and predictably pathogenic, and one duplication c.1269_1276dup p.(Ser426*) (Figure 1A and B, and Supplemental Table S1). None of these variants, but c.1256G>A, were previously reported in the literature.

Immunoblotting of whole-cell extracts revealed a decreased abundance of mutant mtPheRS in all three patients' fibroblasts suggesting a structurally destabilizing role of the identified mutations (Figure 2A). Examination of the abundance of mtDNA and nuclear-encoded OXPHOS proteins revealed a pattern of changes in their abundance consistent with impaired mitochondrial translation—decreased abundance of the mtDNA-encoded COXII protein and some, but not all, nuclear-encoded OXPHOS proteins *(16)*, revealing multiple OXPHOS deficiency where CI and CIV are affected (Figure 2B). Interestingly, unlike COXII, the abundance of the mtDNA-encoded ATP8 was unchanged, probably because it contains a single phenylalanine whereas COXII contains ten (Figure 2B).

Discussion

Our report expands the genetic spectrum of *FARS2*-linked pathologies with four novel pathogenic variants whose causal role was supported by bioinformatics and biochemical analyses. Clinically, these mutations conform to previously established presentations of *FARS2* mutations. Early-onset epileptic phenotype—typically myoclonic epilepsy—is commonly seen in *FARS2* patients and is invariably associated with developmental delay and a wide range of brain abnormalities. Most patients with this phenotype died before two years of age whereas two patients with juvenile onset epilepsy died soon after it became refractory *(11)*. Two of the patients reported here, Pts 2 and 3, also presented an early-onset epilepsy, with mainly myoclonic pharmaco-resistant seizures, but were alive at the age of 16 and 5 years, respectively, suggesting that in some cases the early-epileptic phenotype can be associated with non-fatal disease. This is similar to another *FARS2* patient reported in the literature who presented with generalized epilepsy at age of 19 months and was alive at 17 years of age *(9)*.

Even though mutations in different mitochondrial tRNA synthetases consistently result in neurological phenotypes, these are generally not specific to individual enzymes including *FARS2*—early-onset epilepsy and HSP are genetically heterogeneous and not necessarily linked to tRNA aminoacylation. Moreover, there is no apparent correlation between the location of different *FARS2* mutations along the mtPheRS polypeptide and the type, onset and severity of disease as, for example, mutations affecting the catalytic domain are just as likely to cause an epileptic phenotype as mutations affecting the ABD domain. This prevents us from establishing precise genotype-phenotype correlations. Most likely, the specific structural and functional effects of each mutation intersect with the genetic background to determine the extent to which $tRNA^{Phe}$ aminoacylation is impacted in each individual and the specific clinical presentation in

that individual. For example, of the variants reported here, p.(Arg419His) was previously identified in a patient with pediatric spastic paraplegia and encephalopathy *(17)*. Like this patient, Pt 1 had a non-fatal disease and did not present any epileptic phenotype. Although similar, the two phenotypes were not identical, which may result from the fact that the patient reported by Jou and colleagues was hemizygous whereas Pt 1 is compound heterozygous wherein p.(Arg419His) is co-expressed with a C-terminally truncated mtPheRS. Pt 3 also expressed the p.(Arg419His) variant but deviated from the other two patients in that it also had epileptic phenotype and white-matter degeneration resulting in a relatively more severe disease. In this case, too, the p.(Arg419His) variant is co-expressed with another mtPheRS mutant, p.(His84Pro), which may contribute to the specific phenotype observed in the patient. Thus, phenotypic differences in these cases may result from different genetic modifiers and/or the fact that in Pts 1 and 3 the p.(Arg419His) mutation is co-expressed with two other variants that may functionally interact during aminoacylation. Keeping in mind the small number of patients, it appears that the p.(Arg419His) variant is associated with non-fatal disease with or without epilepsy and white matter abnormalities. In the absence of *in vitro* activity data, we speculate that even though Arg419 is a structurally-important amino acid, its exchange to proline results in a semi-functional enzyme in manner similar to that proposed for p.(Arg419Cys) which resulted in spastic paraplegia and only transient epileptic seizures *(12,18)*.

Our data further expands the genetic spectrum of *FARS2* mutations and rises awareness that some patients may present with non-fatal early-onset epilepsy. As many patients with *FARS2* mutations are compound heterozygous for two missense mutations it would be interesting to integrate data from in vitro activity assays of individual and combined mutant mtPheRS to determine to what extent, or if at all, different mutant mtPheRS interact functionally and whether

this could add additional information that can help explain the phenotypic presentations observed in different patients.

Acknowledgements

We thank the patients and their families for participating in this study.

Conflict of Interest

The authors have no competing financial interests

Funding

Grant Numbers: AFM-TELETHON, nr. 19876, nr. 22529, nr. 22251; ANR, GENOMIT ANR-15-RAR3-0012-07

References

1. Klipcan L, Levin I, Kessler N, Moor N et al. (2008) The tRNA-induced conformational activation of human mitochondrial phenylalanyl-tRNA synthetase. Structure 16 (7):1095-1104. doi:10.1016/j.str.2008.03.020

2. Yadavalli SS, Klipcan L, Zozulya A, Banerjee R et al. (2009) Large-scale movement of functional domains facilitates aminoacylation by human mitochondrial phenylalanyl-tRNA synthetase. FEBS Lett 583 (19):3204-3208. doi:10.1016/j.febslet.2009.09.008

3. Elo JM, Yadavalli SS, Euro L, Isohanni P et al. (2012) Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum Mol Genet 21 (20):4521-4529. doi:10.1093/hmg/dds294

4. Shamseldin HE, Alshammari M, Al-Sheddi T, Salih MA et al. (2012) Genomic analysis of mitochondrial diseases in a consanguineous population reveals novel candidate disease genes. J Med Genet 49 (4):234-241. doi:10.1136/jmedgenet-2012-100836

5. Almalki A, Alston CL, Parker A, Simonic I et al. (2014) Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset epilepsy and cytochrome c oxidase deficiency. Biochimica et biophysica acta 1842 (1):56-64. doi:10.1016/j.bbadis.2013.10.008

6. Walker MA, Mohler KP, Hopkins KW, Oakley DH et al. (2016) Novel Compound Heterozygous Mutations Expand the Recognized Phenotypes of FARS2-Linked Disease. J Child Neurol 31 (9):1127-1137. doi:10.1177/0883073816643402

7. Raviglione F, Conte G, Ghezzi D, Parazzini C et al. (2016) Clinical findings in a patient with FARS2 mutations and early-infantile-encephalopathy with epilepsy. Am J Med Genet A 170 (11):3004-3007. doi:10.1002/ajmg.a.37836

8. Cho JS, Kim SH, Kim HY, Chung T et al. (2017) FARS2 mutation and epilepsy: Possible link with early-onset epileptic encephalopathy. Epilepsy Res 129:118-124. doi:10.1016/j.eplepsyres.2016.11.022

9. Vantroys E, Larson A, Friederich M, Knight K et al. (2017) New insights into the phenotype of FARS2 deficiency. Mol Genet Metab 122 (4):172-181. doi:10.1016/j.ymgme.2017.10.004

10. Almannai M, Wang J, Dai H, El-Hattab AW et al. (2018) FARS2 deficiency; new cases, review of clinical, biochemical, and molecular spectra, and variants interpretation based on structural, functional, and evolutionary significance. Mol Genet Metab 125 (3):281-291. doi:10.1016/j.ymgme.2018.07.014

11. Chen Z, Zhang Y (2019) A patient with juvenile-onset refractory status epilepticus caused by two novel compound heterozygous mutations in FARS2 gene. Int J Neurosci 129 (11):1094-1097. doi:10.1080/00207454.2019.1634071

12. Vernon HJ, McClellan R, Batista DA, Naidu S (2015) Mutations in FARS2 and non-fatal mitochondrial dysfunction in two siblings. Am J Med Genet A 167A (5):1147-1151. doi:10.1002/ajmg.a.36993

13. Yang Y, Liu W, Fang Z, Shi J et al. (2016) A Newly Identified Missense Mutation in FARS2 Causes Autosomal-Recessive Spastic Paraplegia. Hum Mutat 37 (2):165-169. doi:10.1002/humu.22930

14. Sahai SK, Steiner RE, Au MG, Graham JM et al. (2018) FARS2 mutations presenting with pure spastic paraplegia and lesions of the dentate nuclei. Ann Clin Transl Neurol 5 (9):1128-1133. doi:10.1002/acn3.598

15. Barcia G, Rio M, Assouline Z, Zangarelli C et al. (2019) Clinical, neuroimaging and biochemical findings in patients and patient fibroblasts expressing ten novel GFM1 mutations. Hum Mutat. doi:10.1002/humu.23937

16. Ruzzenente B, Assouline Z, Barcia G, Rio M et al. (2018) Inhibition of mitochondrial translation in fibroblasts from a patient expressing the KARS p.(Pro228Leu) variant and presenting with sensorineural deafness, developmental delay, and lactic acidosis. Hum Mutat 39 (12):2047-2059. doi:10.1002/humu.23657

17. Jou C, Ortigoza-Escobar JD, O'Callaghan MM, Nascimento A et al. (2019) Muscle Involvement in a Large Cohort of Pediatric Patients with Genetic Diagnosis of Mitochondrial Disease. J Clin Med 8 (1). doi:10.3390/jcm8010068

18. Kartvelishvili E, Tworowski D, Vernon H, Moor N et al. (2017) Kinetic and structural changes in HsmtPheRS, induced by pathogenic mutations in human FARS2. Protein Sci 26 (8):1505-1516. doi:10.1002/pro.3176

Table 1. Clinical characterization of Pts1, 2 and 3.

Patient, sex, origin, age at the follow-up	*FARS2* mutations	Clinical summary at onset and during follow-up	Brain MRI	Biochemistry
Pt1, Female, French and Chinese origin 8 years	Compound heterozygous c.1256G>A p.(Arg419His) c.1269_1276dup p.(Ser426*)	Regular pregnancy. BW: 2,471g (<5th percentile), BL: 44.5 cm (<5th percentile); BHC: 32.5cm (<5th percentile); Apgar score 7-9. Presentation < 1 month with axial hypotonia and developmental delay; Head control was acquired at 10 months and she could sit at 2 years. No signs of liver failure. No epileptic seizures. EEG recording (repeated during the follow-up): normal background activity and physiological organization during sleep and wakefulness. Electromyography and nerve conduction were normal. At 8 years: spastic tetraparesis, dystonic movements, and axial hypotonia. Unable to walk unassisted. Dysarthric language, able to write using a keyboard. No psychomotor regression episodes, but stagnation periods concomitant with febrile episodes during the first 3 years of life.	Normal at 1 and 2.2 years Mild ventriculomegaly, no enlargement of the subarachnoid spaces (3.5 years)	Transient increase in PL: 1.4-2.9 mmol/l (normal range 0.7-1.8) PP: 0.12-0.15 mmol/l (normal range 0.08-0.17) Lactate/pyruvate ratio: 16-19 (normal range 6-14) OXPHOS: ↓CI in muscle ↓CI+IV in fibroblasts
Pt2, Female, French origin, 16 years	Compound heterozygous c.989G>A p.(Arg330His) c.1113G>T p.(Leu371Phe)	Regular pregnancy. Normal growth parameters at birth; Apgar score 10/10. 6 weeks: neurological distress, global hypotonia. No signs of liver failure. Severe psychomotor delay. No head control. No visual contact. Can react to auditive stimuli. From 19 months, started to present myoclonic focal and generalized seizures that were resistant to antiepileptic treatment composed by phenytoin, vigabatrin, topiramate, lamotrigine, and clonazepam in variable combinations. EEG showed spikes and poly-spikes discharges predominating on occipital regions, activated by intermittent photic stimulation (IPS). At 16 years: spastic tetraparesis and severe muscular atrophy predominating on inferior limbs. Mild scoliosis.	Marked ventriculomegaly, enlargement of the subarachnoid spaces due to white matter loss, especially in the sylvian fissures, abnormal T2 hyperintensities in the lentiform nuclei and dorsal brainstem (4 months, 15 years), cerebellar atrophy. Proton MR spectrum from the basal ganglia shows elevated lactates (15 years).	PL 2.5.-4.8 mmol/l (<2.20 mmol/l) PP: 0.21 mmol/l (normal range 0.08-0.17) Lactate/pyruvate ratio: 13.7-16.6 (normal range 6-14) CSF -L: 9.3 mmol/l (normal range: 1.4-2.2) OXPHOS: ↓CIV in muscle and fibroblasts
Pt3, Male, French origin, 5 years	Compound heterozygous c.1256G>A p.(Arg419His) c.251A>C p.(His84Pro)	Regular pregnancy. Normal growth parameters at birth; Apgar score: 10/10. Global hypotonia since birth. No signs of liver failure. Severe psychomotor delay. Partial head control at 10 months. Myoclonic generalized and focal seizures since the first year of life that were partially controlled by levetiracetam, clonazepam and piracetam. EEG showed spikes and poly-spikes discharges predominating on occipital regions. At 5 years: global hypotonia and lumbar mild scoliosis. He cannot sit unaided, has good contact, but no verbal language. He has nasogastric feeding.	Moderate ventriculomegaly and enlargement of the subarachnoid spaces. Dentate nuclei, brainstem, and pallidal T2 hyperintensity at the age of 1 and 3 years. Normal spectroscopy.	PL: 2.6-4.8mmol/l (normal range 0.7-1.8) PP: 7.8 mmol/l (normal range 0.08-0.17) CSF-L: 5.8mmol/l (normal range: 1.4-2.2) Normal liver enzymes OXPHOS: ↓CIV in fibroblasts

Accession numbers: FARS2 cDNA: NM_001318872.1; mtPheRS: NP_001305801.1, The normal ranges for the different biochemical indicators are indicated in the brackets.

List of abbreviation: BW, birth weigh; BL, birth length; BHC, birth head circumference; CSF-L, lactate in cerebral-spinal fluid; PL, plasma lactate; PP, plasma pyruvate.

Figure legends

Figure 1. Family pedigrees, neuroimaging findings in patients carrying *FARS2* variants and evolutionary conservation of the amino acids affected by these variants (A) Segregation of the newly identified *FARS2* variants into the pedigrees of the three reported families. (B) Axial T2-weighted images showing mild ventriculomegaly, no enlargement of the subarachnoid spaces in Pt 1; marked ventriculomegaly, enlargement of the subarachnoid spaces due to white matter loss, especially in the sylvian fissures, abnormal T2 hyperintensities in the lentiform nuclei and dorsal brainstem in Pt 2; moderate ventriculomegaly and enlargement of the subarachnoid spaces in Pt 3. (C) Linear map of the mtPheRS protein indicating its domain organization and position of the identified mutations. Evolutionary conservation of the amino acids affected by the newly described missense variants is shown in a multisequence alignment of mtPheRS proteins from different species.

Figure 2. Immunoblot analysis of control and patient fibroblasts revealing decreased abundance of mtPheRS and different OXPHOS proteins consistent with impaired mitochondrial translation. (A) Immunoblot analysis of whole-cell extracts from control (C1 and C2) and patient (Pt 1, Pt 2, Pt 3) fibroblasts showing decreased abundance of mtPheRS. β-actin was used as a loading control. (B) Immunoblot analysis of whole-cell extracts from control (C1 and C2) and patient (Pt 1, Pt 2, Pt 3) fibroblasts showing decreased abundance of mtDNA-encoded COXII (OXPHOS complex IV) and nuclear-encoded NDUFA13 (OXPHOS complex I) and COXIV (OXPHOS complex IV). Abundance of SDHA (OXPHOS complex II), ATP5A (OXPHOS complex V) and the mtDNA-encoded subunit ATP8 was unchanged. β-actin was used as a loading control.


A
Family 1
c.1256G>A
p.(Arg419His)
c.1269_1276dup
p.(Ser426*)
Pt 1
c.1256G>A; 1269_1276dup
p.(Arg419His); p.(Ser426*)
Family 2
c.989G>A
p.(Arg330His)
c.1113G>T
p.(Leu371Phe)
Pt 2
c.989G>A; 1113G>T
p.(Arg330His); p.(Leu371Phe)
Family 3
c.1256G>A
p.(Arg419His)
c.251A>C
p.(His84Pro)
Pt 3
c.1256G>A; 251A>C
p.(Arg419His); p.(His84Pro)
B
Pt 1
Pt 2
Pt 3
C
MTS
N-terminal domain
catalytic domain
linker
anticodon-binding domain
451 aa
His84Pro
Arg330His
Leu371Phe
Arg419His
Ser426*
Patient QQHPPLW PDIHLFW SFWFPSE ITYHHME
Homo sapiens QQHHPLW PDIRLFW SFWLPSE ITYRHME
Pan troglodytes QQHHPLW PDIRLFW SFWLPSE ITYRHME
Rat norvegicus QKFHPLW PDIRLFW SFWLPSE ITYRHME
Mus musculus QKFHPLW PDIRLFW SFWLPSE ITYRHME
Canis familiaris QQHHPLW PDIRLFW SFWLPSE ITYRHME
Gallus gallus KKHHPLW PDIRLFW SFWLPTE IVYRHPE
Danio rerio RPHHPLW PDIRLFW SFWLPAE LVYRHME
Caenorhabditis elegans ESSNPLN PDIRLFW SFFLPST IVYRSHE

Figure 1


A
C1
C2
Pt1
Pt2
Pt3
mtPheRS
b-actin
B
C1
C2
Pt1
Pt2
Pt3
SDHA
ATP5A
COX IV
NDUFA13
COX II
ATP8
b-actin
nuclear-encoded
mtDNA-encoded

Figure 2